BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsFinancing

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is

Related news

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-02-20 11:30 EST

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

INBSIntelligent Bio Solutions2026-01-02 22:00 EST

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

INBSIntelligent Bio Solutions2025-12-31 22:20 EST

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BIAFbioAffinity Technologies, Inc.2026-08-14 15:07 EST

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

BIAFbioAffinity Technologies, Inc.2026-08-13 13:07 EST

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

VRAXVirax Biolabs2025-12-04 21:05 EST

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

VRAXVirax Biolabs2025-12-03 18:53 EST

Virax Biolabs Group Limited Announces $5 Million Private Placement

LUCDLucid Diagnostics2026-04-24 14:23 EST

Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

LUCDLucid Diagnostics2026-04-23 12:30 EST

Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

View all latest news

Bluejay Diagnostics

Critical-Care Diagnostics Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform. Symphony Platform Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow. Symphony IL-6...

Recent company news

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Stock data

Close
1.02 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States